Press Releases


AroCell nomination committee for the AGM 2023

AroCell AB (publ.) publishes the nomination committee’s composition for the AGM in 2023.

The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 24th, 2022, consists of the:

  • Clas Runnberg, represents Labbex Förvaltnings AB
  • Jon Eiken, represents his shares
  • Mikael Lönn, represents his shares

Before the annual general meeting 2023, the nomination committee shall prepare a proposal for the election of the chairman and other members of the board of directors, the election of the chairman of the annual meeting, the election of auditors, the determination of fees, and matters pertaining thereto.
 
For more information, please visit:
Nomination committee - AroCell
 
Shareholders who wish to submit proposals to the nomination committee for the annual general meeting 2023 can e-mail info@arocell.com (header ”AroCell´s nomination committee”).
The proposals should be submitted to the nomination committee before January 31st, 2023.

AroCell’s strategic update

AroCell informs that today they will present the company's strategic development and the initiatives and opportunities for 2023 at the Strategy Day starting at 09.30 am.

  • The company's focus on becoming cash flow positive regarding operating activities is developing well.
  • The organic sales growth, including the current order stock, is developing well. Through increased sales resources and strategic partnerships.
  • The company's strong financial position and internal infrastructure enable future product portfolio expansion.
  • New clinical studies are starting as feasibility studies for larger registration studies.

The company has a positive view of the future and can conclude that the work put in has yielded results in the form of good organic sales growth. With a specified five-point strategy as a starting point, AroCell works to increase sales growth while managing the company's cash and cash equivalents with care. The company has a strong financial position, and AroCell's focus on becoming cash flow positive regarding operational activities is developing positively.

"We are actively working to achieve a positive operational cash flow. Our focus on increasing sales has paid off and we are now seeing strong sales growth. This, in combination with streamlining the organization, has taken us quite a way to reach this goal. It is also quite encouraging to see how quickly we have managed to scale up production to meet the increased sales, which demonstrates the resilience of our company," says Anders Hultman, AroCell's CEO.

AroCell has a complete organization that covers the entire value chain from research and development to sales, production, and distribution. The company's infrastructure thus allows an expansion of the product portfolio if the opportunity arises. A larger product offering gives the company increased relevance and attractiveness in current markets and when establishing new ones.

AroCell's clinical strategy is based on studies and approvals that enable launch in new markets. New studies regarding the products TK 210 and UBC will be starting in Europe in the near future. These studies will serve as feasibility studies for larger registration studies and will be the basis for ensuring the most favorable approach to market approval.
 
More information will be presented at the Strategy Day today, at 09:30 live on redeye.se. Welcome!

AroCell AB (publ) Interim Report January 1st to September 30th, 2022

A word from the CEO
"Another eventful and good quarter for AroCell has ended. The positive sales trend continues in our two product areas, oncology and bacteriology. It is particularly pleasing that the sales growth rate within our bacteriological segment increased during the quarter and sales within this segment have now more than doubled compared to the previous year. It feels good to see that our work is paying off. At the same time, we continue to work with our clinical programs and development projects.

Today, AroCell has a very advantageous position. We have a strong cash position, strong sales growth, and an organization that covers everything from research and development to sales, production, and distribution. Thanks to our very dedicated and competent employees, we are now seeing significant progress.”

Anders Hultman, CEO

Reporting period July 1st – September 30th

  • Net sales amounted to 10,401 (6,029) KSEK.
  • Profit after financial items amounted to -11,069 (-17,774) KSEK
  • Cash flow from operating activities for the period amounted to -1,856 (-7,810) KSEK
  • Earnings per share before and after dilution amounted to -0.05 (-0.20) SEK
  • Cash and cash equivalents at the end of the period amounted to 67,825 (27,825) KSEK

Reporting period January 1st – September 30th

  • Net sales amounted to 24,519 (6,102) KSEK
  • Profit after financial items amounted to -42,779 (-30,581) KSEK
  • Cash flow from operating activities for the period amounted to -11,373 (-18,880) KSEK
  • Earnings per share before and after dilution amounted to -0.20 (-0.35) SEK
  • Cash and cash equivalents at the end of the period amounted to 67,825 (27,825) KSEK

Events during the reporting period July 1st – September 30th

  • AroCell expands the collaboration in the Chinese market by including TPS CLIA on Fosun Diagnostics' fully automated system. Through this collaboration, AroCell's market coverage in the Chinese tumor marker market is doubled.
  • AroCell continues to expand globally with new distributors and during the period signed a distribution agreement with Hospimedica covering India, for the sale of UBC® Rapid.

Events after the period

  • The article entitled "Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples", by Kiran Jagarlamudi et al., was published in the journal PLOS One, where the study demonstrated the robustness and simplicity of AroCell’s TK 210 ELISA assay compared to TK activity assays.
  • AroCell continues to expand its business in Africa by signing a distributor agreement with MM African Technology covering Zambia and Malawi. The agreement covers the sale of TUBEX® TF and UBC® Rapid.

Interim report January 1st – September 30th, 2022 (available in Swedish only) (Link)

AroCell AB (publ) Interim Report January 1st to June 30th, 2022

A word from the CEO
”It is with great pleasure that I can state that the positive sales trend continued during the second quarter within our two main segments, oncology and bacteriology. Order intake going forward also looks very good, and it is very satisfying to see that our work is bearing fruit. During the quarter, we validated a new reader for our bladder cancer test and started discussions with Attana AB about managing the production of their consumables in our production facility.”
 
Anders Hultman, CEO
 
Reporting period April 1st – June 30th
·    Net sales amounted to 6,349 (30) KSEK.
·   Profit after financial items amounted to -16,016 (-6,727) KSEK
·   Cash flow from operating activities for the period amounted to -1,397 (-5,185) KSEK
·   Earnings per share before and after dilution amounted to -0.07 (-0.09) SEK
·   Cash and cash equivalents at the end of the period amounted to 69,814 (29,748) KSEK
 
Reporting period January 1st – June 30th
·   Net sales amounted to 14,118 (73) KSEK
·   Profit after financial items amounted to -31,710 (-12,806) KSEK
·   Cash flow from operating activities for the period amounted to -9,517 (-11,421) KSEK
·   Earnings per share before and after dilution amounted to -0.16 (-0.17) SEK
·   Cash and cash equivalents at the end of the period amounted to 69,814 (29,748) KSEK
 
Events during the reporting period April 1st – June 30th
·    Ellen Dittberner was appointed Chief Financial Officer (CFO) as of August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has solid experience, which includes driving change and development work.
 
·    AroCell started discussions with Attana AB regarding moving their production of consumables, for example, sensor chips, to AroCell.
 
·    A new evaluation study of the product TUBEX® TF was started in Uganda. This study is being conducted in collaboration with the Uganda National Public Health Laboratory Services (UNHLS), to evaluate TUBEX® TF. Positive study results will form the basis for an application for market approval followed by sales.
 
·    AroCell held the annual general meeting on 24 May 2022.
 
·    AroCell's quantitative point-of-care (POC) for bladder cancer UBC® Rapid was verified for result interpretation on a new instrument, the Cube Reader. By differentiating UBC® Rapid and meeting the different needs of end users, the possibility of more widespread use increases.
 
·    AroCell acquired 1,313,432 shares in the subsidiary IDL Biotech AB during the second quarter through a compulsory redemption of remaining shares. AroCell now owns all shares in IDL Biotech AB.
 
Interim report January 1st – June 30th, 2022 (available in Swedish only) (Link)

REPORT FROM ANNUAL GENERAL MEETING OF AROCELL AB (PUBL) ON 24 MAY 2022

(Available in Swedish only)

AroCell AB (publ) ("Bolaget") har idag, den 24 maj 2022, hållit årsstämma. Årsstämman beslutade i enlighet med samtliga förslag som styrelsen och valberedningen lagt fram. Stämman genomfördes genom poströstning utan fysiskt deltagande.

Fastställande av balans- och resultaträkningar
Årsstämman fastställde balans- och resultaträkning för bolaget för verksamhetsåret 2021.

Styrelse
Årsstämman beviljade verkställande direktören och styrelsen ansvarsfrihet för 2021 års förvaltning.

Årsstämman beslutade att, för tiden intill slutet av nästa årsstämma, genom omval utse Eva Nordström, Charlotta Ljungqvist och Max Pihlqvist till styrelseledamöter, samt att genom nyval utse Agneta Tufvesson Alm och Johan Häggblad till styrelseledamöter.

Till styrelsens ordförande valdes Johan Häggblad.

Styrelsearvode
Årsstämman beslutade att styrelsearvode för tiden intill nästa årsstämma ska utgå med 250 000 SEK till ordföranden och att styrelsearvode till övriga styrelseledamöter ska utgå med 150 000 SEK.

Revisor
Vidare beslutade årsstämman att genom omval utse Öhrlings PricewaterhouseCoopers AB till revisionsbolag med auktoriserade revisorn Leonard Daun som huvudansvarig revisor för tiden intill slutet av nästa årsstämma.

Beslut om bemyndigande för styrelsen att besluta om nyemission av aktier med eller utan företrädesrätt för Bolagets aktieägare
Stämman beslutade, i enlighet med framlagt förslag, att bemyndiga styrelsen att, vid ett eller flera tillfällen före nästa årsstämma, med eller utan avvikelse från aktieägarnas företrädesrätt, besluta om nyemission av aktier eller emission av konvertibler eller teckningsoptioner.

Antalet aktier, konvertibler eller teckningsoptioner som ska kunna ges ut med stöd av detta bemyndigande genom emissioner utan företrädesrätt för aktieägarna ska vara begränsat på så sätt att antalet aktier efter fulltecknad nyemission, fullt utnyttjande av teckningsoptioner eller full konvertering, inte ökar med mer än 20 procent av vid tidpunkten för denna kallelse utestående aktier.

Beslut om ändring av bolagsordningen
Årsstämman beslutade om att anta ny bolagsordning. Paragraf 3 i bolagsordningen ändras till följande lydelse:

"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt handel och försäljning av produkter och tjänster inom områdena cellbiologi, medicinteknik och diagnostik jämte med detta förenlig verksamhet.".

Fullständiga förslag och beslut
För mer detaljerad information om innehållet i besluten hänvisas till den fullständiga kallelsen till
den extra bolagsstämman. Kallelse till årsstämma samt fullständiga förslag finns tillgängliga på
Bolagets webbplats, www.arocell.com.

AroCell AB (publ) Interim Report January 1st to Mars 31st, 2022

A word from the CEO

”The first quarter of 2022, despite the great unrest we are experiencing in Europe right now, has been a very good quarter. We successfully completed our rights issue and have thereby secured funds, which allows us to implement our strategy. It was also good to see continued very strong sales growth in both our main segments, oncology, and bacteriology during the quarter. Our new organization after the merger is starting to give results and the company is buzzing with activity.”

Anders Hultman, CEO

Reporting period January 1st - Mars 31st

  • Net sales amounted to 7,770 (43) KSEK
  • Profit after financial items amounted to -15,695 (-6,078) KSEK
  • Cash flow from operating activities for the period amounted to -8,120 (-6,235) KSEK
  • Earnings per share before and after dilution amounted to -0.09 (-0.08) SEK
  • Cash and cash equivalents at the end of the period amounted to 90,870 (35,828) KSEK

Events during the reporting period January 1st - Mars 31st

  • A prospectus has been published for the proposed and approved rights issue.
  • AroCell initiated discussions with Attana AB regarding a collaboration. The collaboration aims to give AroCell access to Attana's extensive knowledge in quality and product development, while AroCell's biomarkers could eventually be used on Attana's instruments.
  • During the Extraordinary General Meeting, AroCell's Board was expanded with two new members, Per-Anders Abrahamsson and Max Pihlqvist.
  • The outcome of the rights issue was 100% subscribed for, of which 63% with or without the support of subscription rights. The other 37% were subscribed by the issue guarantors. The Group receives approximately SEK 86 million before deductions for issue costs.
  • On March 8, the Arbitration Board announced a ruling in the compulsory acquisition process between AroCell and IDL's shareholders who did not exchange their shares for AroCell shares in connection with the takeover bid. The price of the IDL share was set at SEK 3.23 per share.
  • The company's headquarters was moved from Uppsala to Stockholm.
  • A directed new issue of shares was carried out to guarantors in connection with the completed rights issue. Where several guarantors chose to receive the guarantee compensation in the form of newly issued shares, a total of 1,134,800 shares comprised, and SEK 851,100.
  • A new screening study with 30 years of follow-up with TK1 was published in the scientific journal The Prostate. Where it could be seen that high concentration levels of TK1 predict early death in prostate cancer.
  • Two new members were proposed by the Nomination Committee prior to the 2022 Annual General Meeting through the election of Johan Häggblad and Agneta Tufvesson Alm.
  • AroCell signed a new distributor agreement with Medionics Healthcare Limited, which covers Kenya and includes sales of TUBEX® TF.

Events after the reporting period

  • Ellen Dittberner was appointed Chief Finance Officer (CFO) in August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has solid experience which includes driving change and development work.

Interim report January 1st - Mars 31st, 2022 (available in Swedish only) (Link)

AroCell appoints new CFO

Ellen Dittberner will take over as Chief Finance Officer (CFO) at AroCell from August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has great experience, which includes driving change and development processes.

Ellen has extensive experience in several different areas such as Group Accounting, Controlling, and Change Management. As CFO, Ellen will be responsible for AroCell Group's finances with associated processes and personnel.
 
Lars Jakobsson will continue in his current role until Ellen takes office and thereafter continue to support AroCell in an advisory role as a consultant, to ensure the continuity of the AroCell Group's finance function and be responsible for a transfer to Ellen.
 
“I am very happy to be able to welcome Ellen as our new CFO at AroCell and look forward to working with her. Ellen's extensive expertise will be a great asset for AroCell in our continued work to grow and develop the company. I would also like to thank Lars for his efforts as CFO. With his solid competence and experience, he has contributed to the business for over 10 years,” says Anders Hultman, AroCells CEO.

Notice of Annual General Meeting of AroCell AB (publ) on 24 May 2022

Available in Swedish only

Aktieägarna i AroCell AB (publ), org.nr 556596-6107, ("AroCell" eller "Bolaget") kallas härmed till årsstämma den 24 maj 2022. Med anledning av covid-19 har Bolagets styrelse beslutat att årsstämman ska genomföras endast genom poströstning. Information om de av bolagsstämman fattade besluten offentliggörs den 24 maj 2022, så snart utfallet av poströstningen är slutligt sammanställt.

Anmälan m.m.
Rätt att deltaga i årsstämman har den som:

  • dels är upptagen som aktieägare i den av Euroclear Sweden AB ("Euroclear") förda aktieboken den 16 maj 2022; rösträttsregistrering gjord senast den 18 maj 2022 kommer dock att beaktas; och
  • dels har anmält sig genom att ha avgett sin poströst enligt instruktionerna under rubriken Anvisningar för poströstning nedan så att poströsten är Computershare AB tillhanda senast 23 maj 2022.

Förvaltarregistrerade aktier
Aktieägare som låtit förvaltarregistrera sina aktier genom bank eller annan förvaltare måste hos förvaltaren begära att föras in i aktieboken hos Euroclear för att kunna delta i stämman (så skallad rösträttsregistrering). Som anges ovan måste förvaltaren ha genomfört rösträttsregistreringen hos Euroclear senast 18 maj 2022. Aktieägare måste därför kontakta sin förvaltare i god tid före denna dag och rösträttsregistrera sina aktier i enlighet med förvaltarens instruktioner.

Anvisningar för poströstning
Styrelsen har beslutat att aktieägarna ska kunna utöva sin rösträtt endast genom poströstning
enligt 22 § lagen (2022:121) om tillfälliga undantag för att underlätta genomförandet av bolags- och
föreningsstämmor.

För poströstningen ska aktieägare använda det formulär för poströstning och följa Bolagets anvisningar som finns tillgängliga på Bolagets webbplats, www.arocell.com, och på Bolagets kontor Karlsbodavägen 39, 168 67 Bromma. Ifyllt och undertecknat formulär skickas med post till Computershare AB, Box 5267, 102 46 Stockholm (märk kuvertet "AroCells årsstämma 2022"). Komplett formulär ska vara Computershare AB tillhanda senast 23 maj 2022. Ifyllt och undertecknat formulär får även inges elektroniskt och ska då skickas till proxy@computershare.se. Aktieägare kan även avge poströst elektroniskt genom verifiering med BankID via Bolagets webbplats, www.arocell.com. Om aktieägare poströstar genom ombud ska fullmakt biläggas formuläret. Fullmaktsformulär tillhandhålls på begäran och finns även tillgängligt på Bolagets webbplats, www.arocell.com. Om aktieägaren är en juridisk person ska registreringsbevis eller annan behörighetshandling biläggas poströstningsformuläret. Aktieägare får inte förse poströsten med särskilda instruktioner eller villkor. Om så sker är hela poströsten ogiltig. Ytterligare anvisningar och villkor finns i poströstningsformuläret.


Fullmakter
Om aktieägare poströstar genom ombud ska en skriftlig och daterad fullmakt undertecknad av
aktieägaren bifogas poströstningsformuläret. Om fullmakten utfärdas av juridisk person ska kopia av registreringsbevis, eller om sådan handling inte finns, motsvarande behörighetshandling bifogas. Fullmaktsformulär på svenska och engelska finns på Bolagets webbplats, www.arocell.com.

Aktieägares rätt att erhålla upplysningar
Styrelsen och verkställande direktören ska, om någon aktieägare begär det och styrelsen anser att det kan ske utan väsentlig skada för Bolaget, lämna upplysningar om förhållanden som kan inverka på bedömningen av ett ärende på dagordningen, förhållanden som kan inverka på bedömningen av Bolagets eller dotterföretags ekonomiska situation och Bolagets förhållande till annat koncernföretag. Begäran om sådana upplysningar ska lämnas skriftligen till Bolaget senast den 14 maj 2022 på adress AroCell AB (publ), Karlsbodavägen 39, 168 67 Bromma (Märk kuvertet "AroCells årsstämma 2022"), eller via e-post direkt till bolagsstamma2022@arocell.com. Upplysningarna lämnas genom att de hålls tillgängliga på Bolagets webbplats och på Bolagets huvudkontor, Karlsbodavägen 39, 168 67 Bromma, senast den 19 maj 2022. Upplysningarna skickas inom samma tid till den aktieägare som har begärt dem och uppgivit sin adress.

Förslag till dagordning
1. Stämmans öppnande
2. Val av ordförande vid stämman
3. Upprättande och godkännande av röstlängd
4. Godkännande av dagordning
5. Val av en eller två personer att justera protokollet
6. Prövning av om stämman blivit behörigen sammankallad
7.
a. Framläggande av årsredovisning för räkenskapsåret 2021
b. Framläggande av revisionsberättelsen för räkenskapsåret 2021
8. Fastställelse av resultaträkning och balansräkning för räkenskapsåret 2021
9. Beslut om dispositioner av Bolagets resultat enligt den fastställda balansräkningen
10. Beslut om ansvarsfrihet för styrelseledamöterna och verkställande direktören
11. Fastställande av antal styrelseledamöter och revisorer
12. Fastställande av arvoden till styrelseledamöter och revisor
13. Val av styrelseledamöter och styrelseordförande
14. Val av revisor
15. Beslut om bemyndigande för styrelsen att emittera aktier, konvertibler eller teckningsoptioner
16. Beslut om ändring av bolagsordningen
17. Stämmans avslutande

Valberedning
Valberedningen har bestått av Jon Eiken, Cleas Runnberg (Labbex Förvaltnings AB) och Mikael Lönn. Jon Eiken har varit valberedningens ordförande.

Beslutsförslag från styrelsen respektive valberedningen

2. Val av ordförande vid stämman
Valberedningen föreslår advokat Henrik Fritz som ordförande vid årsstämman, eller vid förhinder för denne, den som styrelsen i stället anvisar.

3. Upprättande och godkännande av röstlängd
Den röstlängd som föreslås godkänd under punkt 3 på dagordningen är den röstlängd som upprättats av Computershare AB på uppdrag av Bolaget, grundad på bolagsstämmoaktieboken och inkomna poströster, och kontrolleras och tillstyrkt av justeringspersonerna.

5. Val av en eller två personer att justera protokollet
Styrelsen föreslår att en justeringsperson utses, och att Alona Nyberg väljs, eller, vid förhinder, annan
person som föreslås av AroCells styrelse.

9. Beslut om dispositioner av Bolagets resultat enligt den fastställda balansräkningen
Styrelsen föreslår att bolagsstämman beslutar att ansamlad förlust om 176 931 566 SEK samt överkursfond om 376 733 966 SEK balanseras i ny räkning.

10. Beslut om ansvarsfrihet för styrelseledamöterna och verkställande direktören
Revisorn tillstyrker ansvarsfrihet.

11. Fastställande av antal styrelseledamöter och revisorer
Valberedningen föreslår att antalet styrelseledamöter som ska utses av stämman ska vara fem (5)
utan styrelsesuppleanter och att antalet revisorer ska vara en (1) revisor utan suppleanter.

12. Fastställande av arvoden till styrelseledamöter och revisor
Valberedningen föreslår, för tiden intill slutet av nästa årsstämma, arvoden på årsbasis enligt följande och nedan:

  • 250 000 SEK till styrelsens ordförande.
  • 150 000 SEK till var och en av de övriga styrelseledamöterna

Valberedningen föreslår att arvode till revisorn som tidigare ska utgå enligt godkänd räkning.

13. Val av styrelseledamöter och styrelseordförande
Valberedningen föreslår, för tiden intill slutet av nästa årsstämma, omval av Eva Nordström, Charlotta Ljungqvist och Max Pihlqvist samt nyval av Agneta Tufvesson Alm och Johan Häggblad. Valberedningen föreslår vidare nyval av Johan Häggblad till styrelseordförande för tiden intill slutet av nästa årsstämma.

Samtliga styrelseledamöter anses oberoende i förhållande till Bolaget och bolagsledningen och Bolagets större ägare, förutom Max Pihlqvist som är beroende i förhållande till en av Bolagets större ägare.

14. Val av revisor
Valberedningen föreslår att årsstämman för tiden intill slutet av nästa årsstämma omväljer det registrerade revisionsbolaget Öhrlings PricewaterhouseCoopers AB till Bolagets revisor, med auktoriserade revisorn Leonard Daun som huvudansvarig revisor.

15. Beslut om bemyndigande för styrelsen att emittera aktier, konvertibler eller teckningsoptioner
Styrelsen föreslår att årsstämman bemyndigar styrelsen att, vid ett eller flera tillfällen före nästa årsstämma, med eller utan avvikelse från aktieägarnas företrädesrätt, besluta om nyemission av aktier eller emission av konvertibler eller teckningsoptioner. Emission ska kunna ske mot kontant betalning, apport eller kvittning eller i övrigt på marknadsmässiga villkor som styrelsen bestämmer. Om styrelsen beslutar om emission utan företrädesrätt för aktieägarna så ska skälet vara att kunna bredda ägarkretsen, anskaffa eller möjliggöra anskaffning av rörelsekapital, öka likviditeten i aktien, genomföra företagsförvärv eller anskaffa eller möjliggöra anskaffning av kapital för företagsförvärv. Vid beslut om emissioner utan företrädesrätt för aktieägarna ska teckningskursen vara marknadsmässig vid tidpunkten för emissionsbeslutet. Antalet aktier, konvertibler eller teckningsoptioner som ska kunna ges ut med stöd av detta bemyndigande genom emissioner med företrädesrätt för aktieägarna ska rymmas inom gränserna för antalet aktier och aktiekapital i bolagsordningen. Antalet aktier, konvertibler eller teckningsoptioner som ska kunna ges ut med stöd av detta bemyndigande genom emissioner utan företrädesrätt för aktieägarna ska vara begränsat på så sätt att antalet aktier efter fulltecknad nyemission, fullt utnyttjande av teckningsoptioner eller full konvertering, inte ökar med mer än 20 procent av vid tidpunkten för denna kallelse utestående aktier.

Styrelsen föreslår att styrelsens ordförande och verkställande direktören bemyndigas att vidta de smärre justeringar som kan visa sig erforderliga för registrering av beslutet.

16. Beslut om ändring av bolagsordningen
Styrelsen föreslår att årsstämman beslutar att ändra paragraf 3 i bolagsordningen enligt nedan, för att vara förenlig med Bolagets nuvarande verksamhet med anledning av Bolagets förvärv av IDL Biotech AB under föregående räkenskapsår.

Nuvarande lydelseFöreslagen lydelse
§ 3 Verksamhet§ 3 Verksamhet
Föremålet för bolagets verksamhet skall vara forskning och utveckling inom cellbiologi och medicin för kommersiella applikationer som cancerdiagnostik, prognos och behandling och marknadsföring och försäljning av bolagets produkter och tjänster samt annan därmed förenlig verksamhet.Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt handel och försäljning av produkter och tjänster inom områdena cellbiologi, medicinteknik och diagnostik jämte med detta förenlig verksamhet.

Tillgängliga handlingar
Fullständiga beslutsförslag framgår av kallelsen och kommer tillsammans med övrig dokumentation inför stämman kommer att hållas tillgängliga på Bolagets kontor i enlighet med aktiebolagslagens krav samt skickas till de aktieägare som begär det och uppger sin postadress. Handlingarna kommer även hållas tillgängliga på Bolagets webbplats senast den 3 maj 2022, www.arocell.com. Samtliga ovanstående handlingar kommer att framläggas på stämman.

Majoritetskrav
För beslut i enlighet med styrelsens förslag enligt punkterna 15 och 16 krävs att besluten biträds av aktieägare representerande minst två tredjedelar av såväl de avgivna rösterna som de vid stämman företrädda aktierna.

Behandling av personuppgifter
För information om hur personuppgifter behandlas i samband med stämman, se Euroclears och Computershare AB:s respektive integritetspolicyer som finns tillgängliga på deras respektive webbplats, http://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf respektive www.computershare.com/se/gm-gdpr.

Övrig information
Bolaget har vid tiden för utfärdandet av kallelsen 230 361 066 utestående aktier och röster. Bolaget innehar inga egna aktier.

* * * * * * *

Stockholm, april 2022
AroCell AB (publ)
Styrelsen

AroCell’s 2021 Annual Report published

AroCell today announces that the Annual Report for 2021 is now available on the company’s website: www.arocell.com.

The Annual report is available on the following link: https://arocell.com/sv/financial-report/
The report is available in Swedish only.

This information was submitted for publication through the agency of Anders Hultman, on April 7, 2022, at 12:00.

AroCells new Board of Directors proposed for the Annual General Meeting 2022

The Nomination Committee proposes two new board members to AroCells Board of Directors at the 2022 Annual General Meeting through new election of Johan Häggblad and Agneta Tufvesson Alm.

Johan Häggblad has more than 30 years of experience in the pharmaceutical industry in managerial and executive roles. Johan is Chief Scientific Officer at Calliditas. Prior to that, he served as CEO of Pharmalink between 2007 and 2017. His previous management positions were at NeuroNova, Pharmacia Corporation, and Karo Bio AB. Johan has a PhD in neurochemistry and neurotoxicology from Stockholm University and did his postdoc in pharmacology and physiology at New York University and the University of Oxford.

Agneta Tufvesson Alm has more than 30 years of experience in international sales and marketing as well as experience in direct sales in the Nordic countries and the United Kingdom, region and key account management in Europe, Africa, and the Middle East. Agneta has worked with building distribution networks, contract negotiations, management of sales and customer service teams. She currently works at Kemira Kemi AB and has previously held roles at HemoCue AB, Thermo Quest, and Kabi Pharmacia, among others. Agneta has a bachelor's degree in chemistry from Lund University.

The new proposal for the board that proposes the AGM is: Re-election of Eva Nordström, Charlotta Ljungqvist, and Max Pihlqvist, and the new election of Agneta Tufvesson Alm and Johan Häggblad.

The Nomination Committee proposes the new election of Johan Häggblad as the Chairman of the Board.

AroCells Nomination Committee consists of:
Jon Eiken (Chairman)
Mikael Lönn 
Clas Runnberg

AroCell carries out a directed issue of shares to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, GREAT BRITAIN, JAPAN, NEW ZEALAND, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.

AroCell AB (publ) ("AroCell" or the "Company") has completed the rights issue of shares (the "Rights Issue"), which was proposed and announced on 17 December 2021 and approved by the Extraordinary General Meeting on 19 January 2022. In connection herewith, in accordance with the guarantee commitments that have been entered into and what has previously been communicated, a directed issue of shares is carried out to those guarantors in the Rights Issue who have chosen to receive guarantee commission in the form of newly issued shares in the Company (the "Remuneration Issue"). The subscription price in the Remuneration Issue is set at SEK 0.75 per share and payment is made by offsetting the guarantors' claims.

As previously communicated in connection with the Rights Issue, the guarantors had, in accordance with the guarantee commitments entered into, the opportunity to choose to receive guarantee commission in the form of cash compensation or newly issued shares in the Company. A number of guarantors have chosen to receive the guarantee commission in the form of newly issued shares. Due to this, the Board of Directors has, pursuant to the authorization granted by the Extraordinary General Meeting on 19 January 2022, resolved on the Remuneration Issue, which comprises a total of 1,134,800 shares.

Payment in the Remuneration Issue shall be made by offsetting each guarantor’s claim for guarantee commission. The subscription price has been set to SEK 0.75 per share, corresponding to the subscription price in the Rights Issue. Through the Remuneration Issue, the number of shares in AroCell increases by 1,134,800 shares to a total of 226,250,307 shares and increases the share capital by a total of SEK 113,480.00 to SEK 22,625,030.70. The dilution due to the Remuneration Issue amounts to approximately 0.50 per cent.

Advisers
Redeye AB acts as financial adviser and Wigge & Partners Advokat KB acts as legal adviser in connection with the Rights Issue. Nordic Issuing AB acts as issuing agent in connection with the Rights Issue.

For further information, please contact:
Anders Hultman, CEO
Phone: +46 (0)18 50 30 20
Email: anders.hultman@arocell.com

The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on 22 March 2022.

IMPORTANT INFORMATION
The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in AroCell. No action has been taken and measures will not be taken to allow an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in AroCell has only been made through the Prospectus, which was published by the Company on 27 January 2022.

Neither subscription rights, paid subscribed shares (“BTA”) nor newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTAs or newly issued shares have been registered or will be registered under the United States Securities Act of 1933 in its current wording, or under any other applicable law in the United States, Australia, Great Britain, Hong Kong, Japan, Canada, New Zealand, South Africa or in any other country where the Rights Issue or Private Placement or distribution of the press release is contrary to applicable laws or regulations or requires that further prospectuses be prepared, registered or that any other measure is taken in addition to what is required by Swedish law. Accordingly, the press release, as well as the prospectus, application form and other documents attributable to the Rights Issue and Private Placement, may not be distributed to or within any such jurisdiction.

This announcement may include forward-looking statements, which are based on AroCell’s current expectations and projections about future events and financial and operational development. Words such as “intends”, “will”, “expects”, “anticipates”, “may”, “plans”, “estimates”, and other expressions that imply indications or predictions of future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual results may differ materially from what is expressed in forward-looking information.

This information, the opinions, and forward-looking statements contained in this announcement, are applied only at this date and are subject to change without notice. AroCell makes no commitments to disclose updates or revisions to forward-looking information, future events or similar circumstances, other than as required by applicable law

This English announcement is an unofficial translation of the original Swedish announcement. In case of any discrepancies between the Swedish announcement and the English translation, the Swedish announcement shall prevail.

AroCell AB (publ) Interim Report January 1st to December 31st, 2021

A word from the CEO
”2021 has been an exceptional and important year for AroCell, which has been characterized by major changes and a high work pace. The acquisition of IDL Biotech was a significant step forward for AroCell and now the AroCell Group has a strong foundation that creates a good foundation for implementing our strategy.

To be able to continue the commercialization of our existing products, and to develop and apply for regulatory approval for new products and markets, we have completed a new issue of 86 MSEK. Thanks to the support we received from our shareholders in the now completed share issue, we have everything in place to implement our business plan.

It’s reassuring that despite the restrictions inflicted by the COVID 19 pandemic, we see a strong recovery and growth in the oncology segment, we also saw an all-time high in sales in Germany in 2021. Now that COVID restrictions are loosening and more markets are opening up, there is good hope for continued rapid growth in our oncology segment. During the pandemic, AroCell has systematically reached out to new markets for our bacteriology product TUBEX® TF, which we hope to see results of soon. In parallel with this, planning for future clinical studies that will form the basis for several approvals of our products on new markets are ongoing.”

Anders Hultman, CEO

Reporting period October 1st – December 31st

  • Net sales amounted to 5,894 (20) KSEK
  • Profit after financial items amounted to -19,991 (-6,012) KSEK
  • Cash flow from operating activities for the period amounted to -9,423 (-3,834) KSEK
  • Earnings per share before and after dilution amounted to -0.21 (-0.08) SEK

Reporting period January 1st – December 31st
Please note that IDL Biotech is only included in the second half of the year.

  • Net sales* amounted to 11,996 (84) KSEK
  • Profit after financial items amounted to -50,573 (-24,052) KSEK
  • Cash flow from operating activities for the period amounted to -28,206 (-18,902) KSEK
  • Earnings per share before and after dilution amounted to -0.54 (-0.33) KSEK
  • Cash and cash equivalents at the end of the period amounted to 18,402 (42,064) KSEK

*Net sales for the period including IDL Biotech correspond to 23,032 (21,832) KSEK.

Events during the reporting period October 1st – December 31st

  • AroCell informed about the updated operational strategy following the acquisition of IDL Biotech AB. The Group has established a joint office in Bromma so that the operations' strengths and areas of expertise are utilized optimally, to vigorously develop and streamline the newly formed Group.
  • A new study was published that examined whether the concentration of thymidine kinase 1 (TK1) in the blood early shows whether cytotoxic drugs work or not. The measurements were made with AroCell's TK 210 ELISA. The article is authored by Bernhard Tribukait and was published in the journal Cancers, 2021.
  • AroCell continues to expand on the market with new distributors. The Group has signed a distributor agreement with Rock Medical Ltd covering the UK and Northern Ireland for the sale of UBC® Rapid.
  • AroCell's Board of Directors proposed a fully guaranteed rights issue, which was then approved at the Extraordinary General Meeting in January 2022.
  • At the end of the year, AroCell signed a Supply and License agreement with ZECEN Biotech for the distribution of the TPS® CLIA product on all their automated platforms on the Chinese market. The registration process has been initiated with The National Medical Products Administration (NMPA) in China and the product is planned to be available on the Chinese market by the end of 2022.

Events after the reporting period

  • A prospectus has been published for the proposed and approved rights issue.
  • AroCell has initiated a discussion about a collaboration with Attana AB. The collaboration aims to give AroCell access to Attana's extensive knowledge in quality and product development, while AroCell's biomarkers could eventually be used on Attana's instruments.
  • During the Extraordinary General Meeting, AroCell's Board was expanded with two new members, Per-Anders Abrahamsson and Max Pihlqvist.
  • The outcome of the rights issue was 100% subscribed for, of which 63% with or without the support of subscription rights. The other 37% were subscribed by the issue guarantors. The Group receives approximately SEK 86 million before deductions for issue costs.

Interim report January 1st – December 31st, 2021 (available in Swedish only) (Link)

AroCell announces outcome of rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, GREAT BRITAIN, JAPAN, NEW ZEALAND, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.

AroCell AB (publ) (“AroCell” or the “Company”) announces that the Company’s rights issue of shares (the “Rights Issue”), in which the subscription period ended on 14 February 2022, has been completed. The outcome shows that 114,613,133 shares, corresponding to 100 per cent of the Rights Issue have been subscribed. Through the Rights Issue, AroCell receives approximately SEK 86 million before deduction of transaction costs.

Outcome
The outcome shows that 62,294,119 shares, corresponding to approximately 60 per cent of the Rights Issue, have been subscribed for by exercise of subscription rights (including subscription commitments). 2,833,936 shares, corresponding to approximately 3 per cent of the Rights Issue, have been subscribed for without the exercise of subscription rights. Thus, 72,128,055 shares, corresponding to approximately 63 per cent of the Rights Issue, have been subscribed for with and without the exercise of subscription rights. 42,485,078 shares, corresponding to approximately 37 per cent of the Rights Issue, has been subscribed by the guarantors.

Notification regarding allocation
Allocation of shares has been made in accordance with the allocation principles described in the prospectus that was published in connection with the Rights Issue (the "Prospectus"). A notification regarding allocation of shares subscribed for without the exercise of subscription rights will be made by post of a settlement note to each subscriber. Allocated shares subscribed for without the exercise of subscription rights shall be paid for in accordance with the instructions in the settlement note.

Trading in BTA
Trading in paid subscribed shares (Sw. betald tecknad aktie, BTA”) is currently taking place at Nasdaq Stockholm and will cease when the Rights Issue has been registered by the Swedish Companies Registration Office. BTA:s will then be converted to ordinary shares.

Number of shares and share capital
The Rights Issue provides AroCell with proceeds amounting to approximately SEK 86 million before transaction costs. As a result of the Rights Issue, AroCell’s share capital will increase by SEK 11,461,313.30 to a total of SEK 22,922,626.60 and the total number of shares will increase by 114,613,133 shares to 229,226,266 shares.

The Rights Issue in summary

  • Each existing share in the Company held on the record date 26 January 2022 entitled to one (1) subscription right. One (1) subscription right entitled to subscription of one (1) new share, i.e., a subscription ratio of 1:1.
  • The subscription price was SEK 0.75 per new share, which results in the Company receiving issue proceeds of approximately SEK 86 million before deduction of transaction costs.
  • The subscription period ran from and including 31 January 2022 up to and including 14 February 2022.
  • The last day of trading in the AroCell share including the right to participate in the Rights Issue was 24 January 2022.
  • The Company received subscription commitments and entered into agreements on guarantee commitments of approximately SEK 86 million, which secured the Rights Issue up to 100 percent.
  • The Company published the prospectus regarding the Rights Issue on 27 January 2022.

Advisers
Redeye AB acts as financial adviser and Wigge & Partners Advokat KB acts as legal adviser in connection with the Rights Issue. Nordic Issuing AB acts as issuing agent in connection with the Rights Issue.

For further information, please contact:
Anders Hultman, CEO
Phone: +46 (0)18 50 30 20
Email: anders.hultman@arocell.com

The information was submitted for publication, through the agency of the contact persons set out above, at 10:10 a.m. CET on 17 February 2022.

IMPORTANT INFORMATION
The information in this press release does not constitute an offer to acquire, subscribe, or otherwise trade in shares, subscription rights or other securities in AroCell. No action has been taken and measures will not be taken to allow an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in AroCell has only been made through the Prospectus, which was published by the Company on 27 January 2022.

Neither subscription rights, paid subscribed shares (“BTA”) nor newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTAs or newly issued shares have been registered or will be registered under the United States Securities Act of 1933 in its current wording, or under any other applicable law in the United States, Australia, Great Britain, Hong Kong, Japan, Canada, New Zealand, South Africa or in any other country where the Rights Issue or Private Placement or distribution of the press release is contrary to applicable laws or regulations or requires that further prospectuses be prepared, registered or that any other measure is taken in addition to what is required by Swedish law. Accordingly, the press release, as well as the prospectus, application form, and other documents attributable to the Rights Issue and Private Placement, may not be distributed to or within any such jurisdiction.

This announcement may include forward-looking statements, which are based on AroCell’s current expectations and projections about future events and financial and operational development. Words such as “intends”, “will”, “expects”, “anticipates”, “may”, “plans”, “estimates”, and other expressions that imply indications or predictions of future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual results may differ materially from what is expressed in forward-looking information.

This information, the opinions, and forward-looking statements contained in this announcement, are applied only at this date and are subject to change without notice. AroCell makes no commitments to disclose updates or revisions to forward-looking information, future events, or similar circumstances, other than as required by applicable law

This English announcement is an unofficial translation of the original Swedish announcement. In case of any discrepancies between the Swedish announcement and the English translation, the Swedish announcement shall prevail.

AroCell publishes prospectus in connection with forthcoming rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, GREAT BRITAIN, JAPAN, NEW ZEALAND, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.

The Board of Directors of AroCell AB (publ) ("AroCell" or the "Company") has, in connection with the forthcoming rights issue of approximately SEKm 86 (the "Rights Issue"), which was proposed and announced on 17 December 2021, and approved by the Extraordinary General Meeting on 19 January 2022, prepared a Swedish language EU Growth prospectus (the "Prospectus"). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Summary

  • Each existing share in the Company held on the record date 26 January 2022 entitles to one (1) subscription right. One (1) subscription right entitles to subscription of one (1) new share, i.e., a subscription ratio of 1:1.
  • The subscription price is SEK 0.75 per new share, which, assuming the Rights Issue is fully subscribed, results in the Company receiving issue proceeds of approximately SEKm 86 before deduction of transaction costs.
  • The subscription rights are traded on Nasdaq First North Growth Market from and including January 31 2022 up to and including through February 9 2022.
  • The subscription period runs from and including 31 January 2022 up to and including 14 February 2022.
  • The Company has received subscription commitments and has entered into agreements on guarantee commitments of approximately SEKm 86, which secures the Rights issue up to 100 percent.

For complete information on the terms and conditions of the Rights Issue, please see the published Prospectus.

Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on 26 January 2022, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company’s, Nordic Issuing’s and Redeye AB’s respective websites (www.arocell.com, www.nordic-issuing.se, www.redeye.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Subscription forms will be available on the Company's, Nordic Issuing’s, and Redeye AB's respective websites.

Timetable for the Rights Issue

26 January 2022Record date
31 January – 9 February 2022Trading in subscription rights
31 January – 14 February 2022Subscription period
31 January 2022 – Until the Rights Issue is registered at the Swedish Companies Registration OfficeTrading in paid subscription shares (Sw. “BTA”)
Around 17 February 2022Estimated publication of outcome in the Rights Issue

Advisers
Redeye AB acts as financial adviser and Wigge & Partners Advokat KB acts as legal adviser in connection with the Rights Issue. Nordic Issuing AB acts as issuing agent in connection with the Rights Issue.

For further information, please contact:
Anders Hultman, CEO
Phone: +46 (0)18 50 30 20
Email: anders.hultman@arocell.com

This information was submitted for publication, through the agency of the contact person set out above, at 17:35 CET on 27 January 2022.

IMPORTANT INFORMATION
The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in AroCell. No action has been taken and measures will not be taken to allow an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in AroCell will only be made through the Prospectus, which was published by the Company on 26 January 2022.

Neither subscription rights, paid subscribed shares (“BTA”) nor newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTAs or newly issued shares have been registered or will be registered under the United States Securities Act of 1933 in its current wording, or under any other applicable law in the United States, Australia, Great Britain, Hong Kong, Japan, Canada, New Zealand, South Africa or in any other country where the Rights Issue or Private Placement or distribution of the press release is contrary to applicable laws or regulations or requires that further prospectuses be prepared, registered or that any other measure is taken in addition to what is required by Swedish law. Accordingly, the press release, as well as the prospectus, application form and other documents attributable to the Rights Issue and Private Placement, may not be distributed to or within any such jurisdiction.

This announcement may include forward-looking statements, which are based on AroCell’s current expectations and projections about future events and financial and operational development. Words such as “intends”, “will”, “expects”, “anticipates”, “may”, “plans”, “estimates”, and other expressions that imply indications or predictions of future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual results may differ materially from what is expressed in forward-looking information.

This information, the opinions, and forward-looking statements contained in this announcement are applied only at this date and are subject to change without notice. AroCell makes no commitments to disclose updates or revisions to forward-looking information, future events, or similar circumstances, other than as required by applicable law

This English announcement is an unofficial translation of the original Swedish announcement. In case of any discrepancies between the Swedish announcement and the English translation, the Swedish announcement shall prevail.

REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF AROCELL AB (PUBL)

(Available in Swedish only)

AroCell AB (publ) (”Bolaget”) höll idag den 19 januari 2022 en extra bolagsstämma, varvid i huvudsak följande beslut fattades. Vid stämman var 23 287 449 aktier representerade, vilket motsvarar 20,3 procent av totala antalet aktier. Nedan följer en sammanfattning av de beslut som fattades. Besluten fattades enhälligt i enlighet med i kallelsen framlagda förslag.

Ändring av bolagsordningen
Stämman beslutade, i enlighet med styrelsens förslag, om ändring av bolagsordningen avseende § 2 (Styrelsens säte), § 4 (Aktiekapital) och § 5 (Antal aktier).

Företrädesemission av aktier
Stämman beslutade, i enlighet med styrelsens framlagda förslag, om företrädesemission av aktier på de huvudsakliga villkor som följer nedan.

Företrädesemissionen omfattar högst 114 613 133 aktier, innebärande en ökning av aktiekapitalet med högst 11 461 313,3 kronor. För varje befintlig aktie ska varje aktieägare erhålla en teckningsrätt. Varje teckningsrätt ska berättiga till teckning av en (1) ny aktie. För varje tecknad aktie ska erläggas 0,75 kronor. Styrelsen äger rätt att tillåta betalning genom kvittning.

Beslut om bemyndigande för styrelsen att besluta om nyemission av aktier med eller utan företrädesrätt för bolaget aktieägare
Stämman beslutade, i enlighet med styrelsens framlagda förslag, Styrelsen att bemyndiga styrelsen att, vid ett eller flera tillfällen före nästa årsstämma, med eller utan avvikelse från aktieägarnas företrädesrätt, besluta om nyemission av aktier eller emission av konvertibler eller teckningsoptioner.

Antalet aktier, konvertibler eller teckningsoptioner som ska kunna ges ut med stöd av detta bemyndigande genom emissioner utan företrädesrätt för aktieägarna ska vara begränsat på så sätt att antalet aktier efter fulltecknad nyemission, fullt utnyttjande av teckningsoptioner eller full konvertering, inte ökar med mer än 20 procent av vid tidpunkten för denna kallelse utestående aktier.

Antal styrelseledamöter
Stämman beslutade, i enlighet med Labbex Förvaltnings AB:s framlagda förslag, att öka antalet styrelseledamöter från fem till sju styrelseledamöter.

Val av nya styrelseledamöter
Stämman beslutade, i enlighet med Labbex Förvaltnings AB:s framlagda förslag, om nyval av styrelseledamöterna Per-Anders Abrahamsson och Max Pihlqvist. Nuvarande styrelseledamöter Agneta Franksson, Charlotta Ljungqvist, Claes Post, Eva Nordström och Karin Eriksson-Widblom kvarstår som styrelseledamöter, med Claes Post som styrelseordförande.

Fullständiga förslag och beslut
För mer detaljerad information om innehållet i besluten hänvisas till den fullständiga kallelsen till
den extra bolagsstämman. Kallelse till årsstämma samt fullständiga förslag finns tillgängliga på
Bolagets webbplats, www.arocell.com.